OncoMatch/Clinical Trials/NCT06586658
Anti-CD70-CAR-T Cell Injection for the Treatment of Locally Advanced or Relapsed/Metastatic CD70+ Inoperable Renal Cells
Is NCT06586658 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies anti-CD70-CAR-T cells for renal cell carcinoma.
Treatment: anti-CD70-CAR-T cells — This is an investigator-initiated trial to evaluate the role of anti-CD70-CAR T cells in locally advanced or recurrent/metastatic renal cell carcinoma that is inoperable.
Check if I qualifyExtracted eligibility criteria
Cancer type
Renal Cell Carcinoma
Biomarker criteria
Required: CD70 overexpression (CD70+)
advanced malignant renal cell carcinoma of CD70+
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: vegfr inhibitor
Must have received: checkpoint inhibitor
Cannot have received: car-t cell therapy
Cannot have received: anti-cd70 therapy
Lab requirements
Blood counts
Neutrophil absolute value ≥1.5×10^9/L; Hemoglobin ≥80g/L; Platelets ≥75×10^9/L; Lymphocytes (ALC) ≥0.3×10^9/L; no blood transfusion or cell growth factor therapy within 7 days prior to evaluation (2 weeks for long-acting agents such as PEG-rhG-CSF, recombinant erythropoietin allowed)
Kidney function
creatinine ≤1.5×ULN or endogenous creatinine clearance ≥50 mL/min (using Cockcroft Gault formula)
Liver function
serum total bilirubin ≤1.5× ULN (for Gilbert syndrome patients, total bilirubin ≤3×ULN), AST, ALT ≤2.5×ULN; If there is liver metastasis, allow AST, ALT≤5×ULN
Cardiac function
Left ventricular ejection fraction (LVEF) of echocardiography was ≥50%
Have sufficient hematologic function ... Adequate liver function ... Adequate renal function ... Left ventricular ejection fraction (LVEF) of echocardiography was ≥50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify